Phaseline

Targets › ATP5A1

ATP5A1 (ATP synthase F(1) complex subunit alpha, mitochondrial): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 2; Infectious disease; next expected readout May 2027.

Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel. (UniProt, P25705)

Open in Phaseline: the race on ATP5A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boston UniversityBedaquiline
ATP synthase inhibitor
ATP5A1Phase 2Tuberculosis, Multidrug-ResistantMay 2027
Huashan Hospital3-month BDCZ regimen
Combination of bedaquiline (ATP synthase inhibitor), delamanid (mycolic acid inhibitor), c
ATP5A1Phase 2TuberculosisNov 2027
Barwon HealthTelacebec
Mycobacterial ATP synthase inhibitor
ATP5A1Phase 2Buruli UlcerDec 2027

Conditions

Tuberculosis (1) Tuberculosis, Multidrug-Resistant (1) Buruli Ulcer (1)

Modalities

small molecule (3)

Companies

Huashan Hospital (1) Boston University (1) Barwon Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.